Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2010

Open Access 01-12-2010 | Research

Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers

Authors: Kangkang Zhi, Xiaojun Shen, Hao Zhang, Jianwei Bi

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Login to get access

Abstract

Background

The prognosis of gastric cancer patients is difficult to predict because of defects in establishing the surgical-pathological features. Cancer-associated fibroblasts (CAFs) have been found to play prominent role in promoting tumor growth, invasion and metastasis. Thus raises the hypothesis that the extent of CAFs prevalence may help to establish the prognosis of gastric cancer patients.

Methods

Immunochemistry and realtime-PCR experiments were carried out to compare the expression of proteins which are specific markers of CAFs or secreted by CAFs in the tumor and normal tissue specimens. The extent of CAFs' prevalence was graded according to immunochemical staining, and correlation was further analyzed between CAFs' prevalence and other tumor characteristics which may influence the prognosis of gastric cancer patients.

Results

Nearly 80 percent of normal gastric tissues were negative or weak positive for CAFs staining, while more than 60 percent of gastric cancer tissues were moderate or strong positive for CAFs staining. Realtime-PCR results also showed significant elevated expression of FAP, SDF-1 and TGF-β1 in gastric cancer tissues compared to normal gastric tissues. Further analysis showed that CAFs' prevalence was correlated with tumor size, depth of the tumor, lymph node metastasis, liver metastasis or peritoneum metastasis.

Conclusions

Reactive cancer associated fibroblasts (CAFs) were frequently accumulated in gastric cancer tissues, and the prevalence of CAFs was correlated with tumor size, depth of the tumor and tumor metastasis, thus give some supports for establishing the prognosis of the gastric cancer patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Anderson C, Nijagal A, Kim J: Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther. 2006, 10: 345-352.CrossRef Anderson C, Nijagal A, Kim J: Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther. 2006, 10: 345-352.CrossRef
2.
go back to reference Townsend CM, Beauchamp RD, Evers BM, Mattox KL: Sabiston Textbook of Surgery. 2008, Saunders, An Imprinter of Elsevier. Philadelphia, 18 edn Townsend CM, Beauchamp RD, Evers BM, Mattox KL: Sabiston Textbook of Surgery. 2008, Saunders, An Imprinter of Elsevier. Philadelphia, 18 edn
3.
go back to reference Kim JW, Hwang I, Kim MJ, Jang SJ: Clinicopathological characteristics and predictive markers of early gastric cancer with recurrence. J Korean Med Sci. 2009, 24: 1158-1164. 10.3346/jkms.2009.24.6.1158.CrossRef Kim JW, Hwang I, Kim MJ, Jang SJ: Clinicopathological characteristics and predictive markers of early gastric cancer with recurrence. J Korean Med Sci. 2009, 24: 1158-1164. 10.3346/jkms.2009.24.6.1158.CrossRef
4.
go back to reference Miyahara R, Niwa Y, Matsuura T, Maeda O, Ando T, Ohmiya N, Itoh A, Hirooka Y, Goto H: Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years. J Gastroenterol Hepatol. 2007, 22: 1435-1442. 10.1111/j.1440-1746.2007.04991.x.CrossRef Miyahara R, Niwa Y, Matsuura T, Maeda O, Ando T, Ohmiya N, Itoh A, Hirooka Y, Goto H: Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years. J Gastroenterol Hepatol. 2007, 22: 1435-1442. 10.1111/j.1440-1746.2007.04991.x.CrossRef
5.
go back to reference Aurello P, D'Angelo F, Rossi S, Bellagamba R, Cicchini C, Nigri G, Ercolani G, De Angelis R, Ramacciato G: Classification of lymphnode metastases from gastric cancer: comparison between N-site and N-number systems. Our experience and review of the literature. Am Surg. 2007, 73: 359-366. Aurello P, D'Angelo F, Rossi S, Bellagamba R, Cicchini C, Nigri G, Ercolani G, De Angelis R, Ramacciato G: Classification of lymphnode metastases from gastric cancer: comparison between N-site and N-number systems. Our experience and review of the literature. Am Surg. 2007, 73: 359-366.
6.
go back to reference Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer. 2006, 6: 392-401. 10.1038/nrc1877.CrossRef Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer. 2006, 6: 392-401. 10.1038/nrc1877.CrossRef
7.
go back to reference Mueller MM, Fusenig NE: Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004, 4: 839-849. 10.1038/nrc1477.CrossRef Mueller MM, Fusenig NE: Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004, 4: 839-849. 10.1038/nrc1477.CrossRef
8.
go back to reference Bhowmick NA, Neilson EG, Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature. 2004, 432: 332-337. 10.1038/nature03096.CrossRef Bhowmick NA, Neilson EG, Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature. 2004, 432: 332-337. 10.1038/nature03096.CrossRef
9.
go back to reference Tlsty TD, Coussens LM: Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006, 1: 119-150. 10.1146/annurev.pathol.1.110304.100224.CrossRef Tlsty TD, Coussens LM: Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006, 1: 119-150. 10.1146/annurev.pathol.1.110304.100224.CrossRef
10.
go back to reference Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, Trivett M, Thompson ER, Ramakrishna M, Gorringe KL, Polyak K, Haviv I, Campbell IG: No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet. 2008, 40: 650-655. 10.1038/ng.117.CrossRef Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, Trivett M, Thompson ER, Ramakrishna M, Gorringe KL, Polyak K, Haviv I, Campbell IG: No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet. 2008, 40: 650-655. 10.1038/ng.117.CrossRef
11.
go back to reference Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, Wheeler M, Spitler J, Rowley DR: Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res. 2003, 9: 4792-4801. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, Wheeler M, Spitler J, Rowley DR: Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res. 2003, 9: 4792-4801.
12.
go back to reference Lee SJ, Kim JG, Sohn SK, Chae YS, Moon JH, Kim SN, Bae HI, Chung HY, Yu W: No Association of Vascular Endothelial Growth Factor-A (VEGF-A) and VEGF-C Expression with Survival in Patients with Gastric Cancer. Cancer Res Treat. 2009, 41: 218-223. 10.4143/crt.2009.41.4.218.CrossRef Lee SJ, Kim JG, Sohn SK, Chae YS, Moon JH, Kim SN, Bae HI, Chung HY, Yu W: No Association of Vascular Endothelial Growth Factor-A (VEGF-A) and VEGF-C Expression with Survival in Patients with Gastric Cancer. Cancer Res Treat. 2009, 41: 218-223. 10.4143/crt.2009.41.4.218.CrossRef
13.
go back to reference Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59: 5002-5011. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59: 5002-5011.
14.
go back to reference Bissell MJ, Radisky D: Putting tumours in context. Nat Rev Cancer. 2001, 1: 46-54. 10.1038/35094059.CrossRef Bissell MJ, Radisky D: Putting tumours in context. Nat Rev Cancer. 2001, 1: 46-54. 10.1038/35094059.CrossRef
15.
go back to reference Polyak K, Haviv I, Campbell IG: Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009, 25: 30-38. 10.1016/j.tig.2008.10.012.CrossRef Polyak K, Haviv I, Campbell IG: Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009, 25: 30-38. 10.1016/j.tig.2008.10.012.CrossRef
16.
go back to reference Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D, Cunha GR: Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. 2001, 61: 8135-8142. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D, Cunha GR: Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res. 2001, 61: 8135-8142.
17.
go back to reference Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL: Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene. 2005, 24: 5053-5068. 10.1038/sj.onc.1208685.CrossRef Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL: Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene. 2005, 24: 5053-5068. 10.1038/sj.onc.1208685.CrossRef
18.
go back to reference Cheng N, Chytil A, Shyr Y, Joly A, Moses HL: Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res. 2007, 67: 4869-4877. 10.1158/0008-5472.CAN-06-3381.CrossRef Cheng N, Chytil A, Shyr Y, Joly A, Moses HL: Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res. 2007, 67: 4869-4877. 10.1158/0008-5472.CAN-06-3381.CrossRef
19.
go back to reference Noel A, De Pauw-Gillet MC, Purnell G, Nusgens B, Lapiere CM, Foidart JM: Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. Br J Cancer. 1993, 68: 909-915.CrossRef Noel A, De Pauw-Gillet MC, Purnell G, Nusgens B, Lapiere CM, Foidart JM: Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. Br J Cancer. 1993, 68: 909-915.CrossRef
20.
go back to reference Guo X, Oshima H, Kitmura T, Taketo MM, Oshima M: Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer. J Biol Chem. 2008, 283: 19864-19871. 10.1074/jbc.M800798200.CrossRef Guo X, Oshima H, Kitmura T, Taketo MM, Oshima M: Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer. J Biol Chem. 2008, 283: 19864-19871. 10.1074/jbc.M800798200.CrossRef
21.
go back to reference Gabbiani G, Kapanci Y, Barazzone P, Franke WW: Immunochemical identification of intermediate-sized filaments in human neoplastic cells. A diagnostic aid for the surgical pathologist. Am J Pathol. 1981, 104: 206-216. Gabbiani G, Kapanci Y, Barazzone P, Franke WW: Immunochemical identification of intermediate-sized filaments in human neoplastic cells. A diagnostic aid for the surgical pathologist. Am J Pathol. 1981, 104: 206-216.
22.
go back to reference Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG: Identification and characterization of a fibroblast marker: FSP1. J Cell Biol. 1995, 130: 393-405. 10.1083/jcb.130.2.393.CrossRef Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG: Identification and characterization of a fibroblast marker: FSP1. J Cell Biol. 1995, 130: 393-405. 10.1083/jcb.130.2.393.CrossRef
23.
go back to reference Iwano M, Fischer A, Okada H, Plieth D, Xue C, Danoff TM, Neilson EG: Conditional abatement of tissue fibrosis using nucleoside analogs to selectively corrupt DNA replication in transgenic fibroblasts. Mol Ther. 2001, 3: 149-159. 10.1006/mthe.2000.0251.CrossRef Iwano M, Fischer A, Okada H, Plieth D, Xue C, Danoff TM, Neilson EG: Conditional abatement of tissue fibrosis using nucleoside analogs to selectively corrupt DNA replication in transgenic fibroblasts. Mol Ther. 2001, 3: 149-159. 10.1006/mthe.2000.0251.CrossRef
24.
go back to reference Christiansen VJ, Jackson KW, Lee KN, McKee PA: Effect of fibroblast activation protein and [alpha]2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch Biochem Biophys. 2007, 457: 177-186. 10.1016/j.abb.2006.11.006.CrossRef Christiansen VJ, Jackson KW, Lee KN, McKee PA: Effect of fibroblast activation protein and [alpha]2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch Biochem Biophys. 2007, 457: 177-186. 10.1016/j.abb.2006.11.006.CrossRef
25.
go back to reference Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, Cotter RJ, Denmeade SR: Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry. 2008, 47: 1076-1086. 10.1021/bi701921b.CrossRef Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, Cotter RJ, Denmeade SR: Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry. 2008, 47: 1076-1086. 10.1021/bi701921b.CrossRef
26.
go back to reference Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, Hoffman JP, Weiner LM, Cheng JD: Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008, 37: 154-158. 10.1097/MPA.0b013e31816618ce.CrossRef Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, Hoffman JP, Weiner LM, Cheng JD: Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008, 37: 154-158. 10.1097/MPA.0b013e31816618ce.CrossRef
27.
go back to reference Garin-Chesa P, Old LJ, Rettig WJ: Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. PNAS. 1990, 87: 7235-7239. 10.1073/pnas.87.18.7235.CrossRef Garin-Chesa P, Old LJ, Rettig WJ: Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. PNAS. 1990, 87: 7235-7239. 10.1073/pnas.87.18.7235.CrossRef
28.
go back to reference Goscinski MA, Suo Z, Flørenes VA, Vlatkovic L, Nesland JM, Giercksky KE: FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions. Ultrastruct Pathol. 2008, 32: 89-96. 10.1080/01913120802034934.CrossRef Goscinski MA, Suo Z, Flørenes VA, Vlatkovic L, Nesland JM, Giercksky KE: FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions. Ultrastruct Pathol. 2008, 32: 89-96. 10.1080/01913120802034934.CrossRef
29.
go back to reference Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT, Cheng JD: Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007, 13: 1736-1741. 10.1158/1078-0432.CCR-06-1746.CrossRef Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT, Cheng JD: Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007, 13: 1736-1741. 10.1158/1078-0432.CCR-06-1746.CrossRef
30.
go back to reference Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, Old LJ, Rettig WJ: Molecular cloning of fibroblast activation protein a, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. PNAS. 1994, 91: 5657-5661. 10.1073/pnas.91.12.5657.CrossRef Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, Old LJ, Rettig WJ: Molecular cloning of fibroblast activation protein a, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. PNAS. 1994, 91: 5657-5661. 10.1073/pnas.91.12.5657.CrossRef
31.
go back to reference Santos AM, Jung J, Aziz N, Kissil JL, Puré E: Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009, 119: 3613-3625. 10.1172/JCI38988.CrossRef Santos AM, Jung J, Aziz N, Kissil JL, Puré E: Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009, 119: 3613-3625. 10.1172/JCI38988.CrossRef
32.
go back to reference Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005, 121: 335-348. 10.1016/j.cell.2005.02.034.CrossRef Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005, 121: 335-348. 10.1016/j.cell.2005.02.034.CrossRef
33.
go back to reference Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW: Crosstalk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res. 2007, 67: 4244-4253. 10.1158/0008-5472.CAN-06-3946.CrossRef Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW: Crosstalk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res. 2007, 67: 4244-4253. 10.1158/0008-5472.CAN-06-3946.CrossRef
34.
go back to reference Vindrieux D, Escobar P, Lazennec G: Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer. 2009, 16: 663-673. 10.1677/ERC-09-0109.CrossRef Vindrieux D, Escobar P, Lazennec G: Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer. 2009, 16: 663-673. 10.1677/ERC-09-0109.CrossRef
35.
go back to reference Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR: Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res. 2002, 62: 6021-6025. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR: Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res. 2002, 62: 6021-6025.
36.
go back to reference Shimoda M, Mellody KT, Orimo A: Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol. 2010, 21: 19-25. 10.1016/j.semcdb.2009.10.002.CrossRef Shimoda M, Mellody KT, Orimo A: Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol. 2010, 21: 19-25. 10.1016/j.semcdb.2009.10.002.CrossRef
37.
go back to reference de la Peña S, L Sampieri C, León-Córdoba K: Matrix metalloproteases as molecular markers in gastric cancer. Med Clin (Barc). 2010, 134: 123-126. 10.1016/j.medcli.2009.09.031.CrossRef de la Peña S, L Sampieri C, León-Córdoba K: Matrix metalloproteases as molecular markers in gastric cancer. Med Clin (Barc). 2010, 134: 123-126. 10.1016/j.medcli.2009.09.031.CrossRef
38.
go back to reference Ge J, Chen Z, Wu S, Chen J, Li X, Li J, Yin J, Chen Z: Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion. 2009, 80: 148-158. 10.1159/000226089.CrossRef Ge J, Chen Z, Wu S, Chen J, Li X, Li J, Yin J, Chen Z: Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion. 2009, 80: 148-158. 10.1159/000226089.CrossRef
39.
go back to reference Gao P, Zhou GY, Zhang QH, Su ZX, Zhang TG, Xiang L, Wang Y, Zhang SL, Mu K: Lymphangiogenesis in gastric carcinoma correlates with prognosis. J Pathol. 2009, 218: 192-200. 10.1002/path.2523.CrossRef Gao P, Zhou GY, Zhang QH, Su ZX, Zhang TG, Xiang L, Wang Y, Zhang SL, Mu K: Lymphangiogenesis in gastric carcinoma correlates with prognosis. J Pathol. 2009, 218: 192-200. 10.1002/path.2523.CrossRef
Metadata
Title
Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers
Authors
Kangkang Zhi
Xiaojun Shen
Hao Zhang
Jianwei Bi
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-29-66

Other articles of this Issue 1/2010

Journal of Experimental & Clinical Cancer Research 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine